Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study

BACKGROUND: Exit strategy after natalizumab cessation in multiple sclerosis (MS) is a crucial point because the risk of disease reactivation is high during this period. The objective of this observational study was to compare ocrelizumab to fingolimod after natalizumab cessation in patients with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigaut, Kévin, Kremer, Laurent, Fabacher, Thibaut, Ahle, Guido, Goudot, Mathilde, Fleury, Marie, Gaultier, Claude, Courtois, Sylvie, Collongues, Nicolas, de Seze, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725429/
https://www.ncbi.nlm.nih.gov/pubmed/34982200
http://dx.doi.org/10.1007/s00415-021-10950-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725429/
https://www.ncbi.nlm.nih.gov/pubmed/34982200
http://dx.doi.org/10.1007/s00415-021-10950-7

Ejemplares similares